A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 420 participants.

Also called NCT02298192

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 420 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02298192
  • EudraCT 2012-004625-25
Main results
  • Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial Diabetes, obesity & metabolism, 2017-06 DOI, PubMed 28124817, PMC5484356 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Austria, Bulgaria, Canada, Czechia, Hungary, Russia, Serbia, Slovakia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02298192. Randomized; no masking; primary purpose treatment. Start 2014-11-21 (actual); primary completion 2015-12-23 (actual). Results posted on 2017-05-23.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms
Acronym
DUAL™ VI
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
insulin degludec/liraglutide
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct02298192
Content hash
2f265dc51f674d204d5ae529656538bedb3557e7bd618cc9d22f0806c3a4d0ac